With this decision, UTHR now has no remaining claims in which it is contesting approval of YUTREPIA for the treatment of PAH after the expiration of NCI exclusivity in May 2025. With the final ...

Navigating patent eligibility under 35 USC § 101 is challenging for artificial intelligence inventions, which are often ...

Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

On July 31, 2024, Adial announced that, after an extensive review of data and information from the Onward Study, it had filed ...

The U.S. patent system is a cornerstone of economic growth and technological advancement, particularly for small businesses, ...

Ashutosh Tripathi is a Senior Engineering Manager who now boasts a software development experience of 16 years.

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

The patent’s claims cover Lipella’s method of using metastable liposomes to deliver therapeutic agents, providing broad intellectual property protection for the company’s drug delivery platform. This ...

Encouraged and abetted by free riders who would benefit unfairly from others’ work, well-intentioned lawmakers and judicial ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...